Hashmi M et al., 2026: The REMAP-CAP ivermectin domain, run in Pakistan, India and Ireland in 2021-22, found ivermectin unlikely to improve organ support-free days or survival in either critically or noncritically ill hospitalized patients.
For critically and noncritically ill hospitalized patients with COVID-19, ivermectin was unlikely to improve the primary composite outcome of organ support-free days and hospital survival.
Hashmi M et al., 2026: The REMAP-CAP ivermectin domain, run in Pakistan, India and Ireland in 2021-22, found ivermectin unlikely to improve organ support-free days or survival in either critically or noncritically ill hospitalized patients. International, multifactorial, adaptive platform randomized controlled trial; hospitals in Pakistan, India and Ireland, June 2021-September 2022; critically ill n=61 analysed (37 ivermectin, 24 control) and noncritically ill n=89 (44 vs 45) at the point of closure; ivermectin vs no ivermectin. Adjusted proportional OR 1.04 (95% CrI 0.48-2.34), posterior probability of superiority 53.7%. Disclosures: Dr Hashmi's institution received funding for REMAP-CAP enrollment and several authors report industry support (see paper). Enrollment was closed for operational reasons, so the sample is small , noted so the row is not read as a large trial. Study type: randomized trial.
